NANOG_HUMAN
ID NANOG_HUMAN Reviewed; 305 AA.
AC Q9H9S0; D3DUU4; Q2TTG0; Q6JZS5;
DT 28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT 28-NOV-2006, sequence version 2.
DT 03-AUG-2022, entry version 175.
DE RecName: Full=Homeobox protein NANOG;
DE AltName: Full=Homeobox transcription factor Nanog;
DE Short=hNanog;
GN Name=NANOG;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ASN-82, AND TISSUE
RP SPECIFICITY.
RC TISSUE=Embryonic stem cell;
RX PubMed=12787504; DOI=10.1016/s0092-8674(03)00393-3;
RA Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K.,
RA Maruyama M., Maeda M., Yamanaka S.;
RT "The homeoprotein Nanog is required for maintenance of pluripotency in
RT mouse epiblast and ES cells.";
RL Cell 113:631-642(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC TISSUE=Embryonic stem cell;
RX PubMed=14990856; DOI=10.1634/stemcells.22-2-169;
RA Clark A.T., Rodriguez R.T., Bodnar M.S., Abeyta M.J., Cedars M.I.,
RA Turek P.J., Firpo M.T., Reijo Pera R.A.;
RT "Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells
RT and map to chromosome 12p13, a hotspot for teratocarcinoma.";
RL Stem Cells 22:169-179(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, DNA-BINDING,
RP TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC TISSUE=Embryonic stem cell;
RX PubMed=16391521; DOI=10.1038/emm.2005.73;
RA Kim J.S., Kim J., Kim B.S., Chung H.Y., Lee Y.Y., Park C.-S., Lee Y.S.,
RA Lee Y.H., Chung I.Y.;
RT "Identification and functional characterization of an alternative splice
RT variant within the fourth exon of human nanog.";
RL Exp. Mol. Med. 37:601-607(2005).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASN-82.
RC TISSUE=Teratocarcinoma;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-82.
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP TISSUE SPECIFICITY.
RX PubMed=12787505; DOI=10.1016/s0092-8674(03)00392-1;
RA Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S.,
RA Smith A.;
RT "Functional expression cloning of Nanog, a pluripotency sustaining factor
RT in embryonic stem cells.";
RL Cell 113:643-655(2003).
RN [7]
RP DEVELOPMENTAL STAGE.
RX PubMed=15108323; DOI=10.1002/dvdy.20034;
RA Hart A.H., Hartley L., Ibrahim M., Robb L.;
RT "Identification, cloning and expression analysis of the pluripotency
RT promoting Nanog genes in mouse and human.";
RL Dev. Dyn. 230:187-198(2004).
RN [8]
RP FUNCTION.
RX PubMed=16000880; DOI=10.1038/emm.2005.33;
RA Oh J.-H., Do H.-J., Yang H.-M., Moon S.-Y., Cha K.-Y., Chung H.-M.,
RA Kim J.-H.;
RT "Identification of a putative transactivation domain in human Nanog.";
RL Exp. Mol. Med. 37:250-254(2005).
RN [9]
RP DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX PubMed=15982323; DOI=10.1111/j.1365-2559.2005.02182.x;
RA Hoei-Hansen C.E., Almstrup K., Nielsen J.E., Brask Sonne S., Graem N.,
RA Skakkebaek N.E., Leffers H., Rajpert-De Meyts E.;
RT "Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes,
RT testicular carcinoma in situ and germ cell tumours.";
RL Histopathology 47:48-56(2005).
RN [10]
RP DEVELOPMENTAL STAGE.
RX PubMed=15582778; DOI=10.1016/j.mod.2004.08.008;
RA Hatano S.Y., Tada M., Kimura H., Yamaguchi S., Kono T., Nakano T.,
RA Suemori H., Nakatsuji N., Tada T.;
RT "Pluripotential competence of cells associated with Nanog activity.";
RL Mech. Dev. 122:67-79(2005).
RN [11]
RP FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX PubMed=15983365; DOI=10.1634/stemcells.2005-0080;
RA Hyslop L.A., Stojkovic M., Armstrong L., Walter T., Stojkovic P.,
RA Przyborski S., Herbert M., Murdoch A., Strachan T., Lako M.;
RT "Downregulation of NANOG induces differentiation of human embryonic stem
RT cells to extraembryonic lineages.";
RL Stem Cells 23:1035-1043(2005).
RN [12]
RP IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH PCGF1.
RX PubMed=26687479; DOI=10.1038/srep18388;
RA Oliviero G., Munawar N., Watson A., Streubel G., Manning G., Bardwell V.,
RA Bracken A.P., Cagney G.;
RT "The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a
RT pluripotency sub-network that includes DPPA4, a regulator of
RT embryogenesis.";
RL Sci. Rep. 5:18388-18388(2015).
RN [13]
RP STRUCTURE BY NMR OF 75-157.
RG Center for eukaryotic structural genomics (CESG);
RT "Solution structure of human stem cell transcription factor NANOG.";
RL Submitted (MAR-2010) to the PDB data bank.
RN [14]
RP X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 94-162 IN COMPLEX WITH DNA,
RP DNA-BINDING, MUTAGENESIS OF PHE-102; LEU-122; GLN-124; MET-125; TYR-136;
RP LYS-137; LYS-140; THR-141; GLN-144; ASN-145; ARG-147; MET-148 AND LYS-151,
RP AND FUNCTION.
RX PubMed=25825768; DOI=10.1073/pnas.1502855112;
RA Hayashi Y., Caboni L., Das D., Yumoto F., Clayton T., Deller M.C.,
RA Nguyen P., Farr C.L., Chiu H.J., Miller M.D., Elsliger M.A., Deacon A.M.,
RA Godzik A., Lesley S.A., Tomoda K., Conklin B.R., Wilson I.A., Yamanaka S.,
RA Fletterick R.J.;
RT "Structure-based discovery of NANOG variant with enhanced properties to
RT promote self-renewal and reprogramming of pluripotent stem cells.";
RL Proc. Natl. Acad. Sci. U.S.A. 112:4666-4671(2015).
RN [15]
RP VARIANT ASN-82.
RX PubMed=15233988; DOI=10.1016/j.ygeno.2004.02.014;
RA Booth H.A., Holland P.W.;
RT "Eleven daughters of NANOG.";
RL Genomics 84:229-238(2004).
CC -!- FUNCTION: Transcription regulator involved in inner cell mass and
CC embryonic stem (ES) cells proliferation and self-renewal. Imposes
CC pluripotency on ES cells and prevents their differentiation towards
CC extraembryonic endoderm and trophectoderm lineages. Blocks bone
CC morphogenetic protein-induced mesoderm differentiation of ES cells by
CC physically interacting with SMAD1 and interfering with the recruitment
CC of coactivators to the active SMAD transcriptional complexes. Acts as a
CC transcriptional activator or repressor. Binds optimally to the DNA
CC consensus sequence 5'-TAAT[GT][GT]-3' or 5'-[CG][GA][CG]C[GC]ATTAN[GC]-
CC 3'. Binds to the POU5F1/OCT4 promoter (PubMed:25825768). Able to
CC autorepress its expression in differentiating (ES) cells: binds to its
CC own promoter following interaction with ZNF281/ZFP281, leading to
CC recruitment of the NuRD complex and subsequent repression of
CC expression. When overexpressed, promotes cells to enter into S phase
CC and proliferation. {ECO:0000269|PubMed:15983365,
CC ECO:0000269|PubMed:16000880, ECO:0000269|PubMed:16391521,
CC ECO:0000269|PubMed:25825768}.
CC -!- SUBUNIT: Interacts with SMAD1 (By similarity). Interacts with SALL4 (By
CC similarity). Interacts with ZNF281/ZFP281 (By similarity). Interacts
CC with PCGF1 (PubMed:26687479). Interacts with ESRRB; reciprocally
CC modulates their transcriptional activities (By similarity). Interacts
CC with NSD2 (By similarity). {ECO:0000250|UniProtKB:Q80Z64,
CC ECO:0000269|PubMed:26687479}.
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00108,
CC ECO:0000269|PubMed:15983365}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=Q9H9S0-1; Sequence=Displayed;
CC Name=2; Synonyms=Nanog-delta 48;
CC IsoId=Q9H9S0-2; Sequence=VSP_021688;
CC -!- TISSUE SPECIFICITY: Expressed in testicular carcinoma and derived germ
CC cell tumors (at protein level). Expressed in fetal gonads, ovary and
CC testis. Also expressed in ovary teratocarcinoma cell line and
CC testicular embryonic carcinoma. Not expressed in many somatic organs
CC and oocytes. {ECO:0000269|PubMed:12787504, ECO:0000269|PubMed:12787505,
CC ECO:0000269|PubMed:14990856, ECO:0000269|PubMed:15982323,
CC ECO:0000269|PubMed:16391521}.
CC -!- DEVELOPMENTAL STAGE: Expressed in embryonic stem (ES) and carcinoma
CC (EC) cells. Expressed in inner cell mass (ICM) of the blastocyst and
CC gonocytes between 14 and 19 weeks of gestation (at protein level). Not
CC expressed in oocytes, unfertilized oocytes, 2-16 cell embryos and early
CC morula (at protein level). Expressed in embryonic stem cells (ES).
CC Expression decreases with ES differentiation.
CC {ECO:0000269|PubMed:15108323, ECO:0000269|PubMed:15582778,
CC ECO:0000269|PubMed:15982323, ECO:0000269|PubMed:15983365,
CC ECO:0000269|PubMed:16391521}.
CC -!- MISCELLANEOUS: Exists an other tandem duplicated non-processed
CC pseudogene (NANOGP1) and 10 other NANOG-related nucleotide sequences
CC located on different chromosomes, all of which are processed
CC pseudogenes lacking introns (NANOGP2 to NANOGP11); except NANOGP8 which
CC is a retrogene.
CC -!- SIMILARITY: Belongs to the Nanog homeobox family. {ECO:0000305}.
CC -!- WEB RESOURCE: Name=Wikipedia; Note=Nanog entry;
CC URL="https://en.wikipedia.org/wiki/Nanog";
CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC Haematology;
CC URL="http://atlasgeneticsoncology.org/Genes/NANOGID46540ch12p13.html";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB093576; BAC76999.1; -; mRNA.
DR EMBL; AY230262; AAP49529.1; -; mRNA.
DR EMBL; AY578089; AAT81526.1; -; mRNA.
DR EMBL; AK022643; BAB14151.1; -; mRNA.
DR EMBL; CH471116; EAW88649.1; -; Genomic_DNA.
DR EMBL; CH471116; EAW88651.1; -; Genomic_DNA.
DR CCDS; CCDS31736.1; -. [Q9H9S0-1]
DR CCDS; CCDS73436.1; -. [Q9H9S0-2]
DR RefSeq; NP_001284627.1; NM_001297698.1. [Q9H9S0-2]
DR RefSeq; NP_079141.2; NM_024865.3. [Q9H9S0-1]
DR PDB; 2KT0; NMR; -; A=75-157.
DR PDB; 4RBO; X-ray; 3.30 A; A/D=94-162.
DR PDBsum; 2KT0; -.
DR PDBsum; 4RBO; -.
DR AlphaFoldDB; Q9H9S0; -.
DR BMRB; Q9H9S0; -.
DR SMR; Q9H9S0; -.
DR BioGRID; 123000; 239.
DR CORUM; Q9H9S0; -.
DR IntAct; Q9H9S0; 3.
DR MINT; Q9H9S0; -.
DR STRING; 9606.ENSP00000229307; -.
DR ChEMBL; CHEMBL3580527; -.
DR iPTMnet; Q9H9S0; -.
DR PhosphoSitePlus; Q9H9S0; -.
DR BioMuta; NANOG; -.
DR DMDM; 118573073; -.
DR EPD; Q9H9S0; -.
DR jPOST; Q9H9S0; -.
DR PaxDb; Q9H9S0; -.
DR PeptideAtlas; Q9H9S0; -.
DR PRIDE; Q9H9S0; -.
DR Antibodypedia; 4521; 1342 antibodies from 49 providers.
DR CPTC; Q9H9S0; 3 antibodies.
DR DNASU; 79923; -.
DR Ensembl; ENST00000229307.9; ENSP00000229307.4; ENSG00000111704.11. [Q9H9S0-1]
DR Ensembl; ENST00000526286.1; ENSP00000435288.1; ENSG00000111704.11. [Q9H9S0-2]
DR GeneID; 79923; -.
DR KEGG; hsa:79923; -.
DR MANE-Select; ENST00000229307.9; ENSP00000229307.4; NM_024865.4; NP_079141.2.
DR UCSC; uc009zfy.2; human. [Q9H9S0-1]
DR CTD; 79923; -.
DR DisGeNET; 79923; -.
DR GeneCards; NANOG; -.
DR HGNC; HGNC:20857; NANOG.
DR HPA; ENSG00000111704; Tissue enhanced (brain).
DR MIM; 607937; gene.
DR neXtProt; NX_Q9H9S0; -.
DR OpenTargets; ENSG00000111704; -.
DR PharmGKB; PA134864904; -.
DR VEuPathDB; HostDB:ENSG00000111704; -.
DR eggNOG; KOG0491; Eukaryota.
DR GeneTree; ENSGT00670000098076; -.
DR HOGENOM; CLU_086240_0_0_1; -.
DR InParanoid; Q9H9S0; -.
DR OMA; AWSNHSW; -.
DR PhylomeDB; Q9H9S0; -.
DR TreeFam; TF337402; -.
DR PathwayCommons; Q9H9S0; -.
DR Reactome; R-HSA-2892245; POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation.
DR Reactome; R-HSA-2892247; POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation.
DR Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR SignaLink; Q9H9S0; -.
DR SIGNOR; Q9H9S0; -.
DR BioGRID-ORCS; 79923; 19 hits in 1025 CRISPR screens.
DR EvolutionaryTrace; Q9H9S0; -.
DR GeneWiki; Homeobox_protein_NANOG; -.
DR GenomeRNAi; 79923; -.
DR Pharos; Q9H9S0; Tbio.
DR PRO; PR:Q9H9S0; -.
DR Proteomes; UP000005640; Chromosome 12.
DR RNAct; Q9H9S0; protein.
DR Bgee; ENSG00000111704; Expressed in pericardium and 68 other tissues.
DR ExpressionAtlas; Q9H9S0; baseline and differential.
DR Genevisible; Q9H9S0; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR GO; GO:0005730; C:nucleolus; IDA:BHF-UCL.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:HGNC-UCL.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; ISS:UniProtKB.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR GO; GO:0030154; P:cell differentiation; IEP:HGNC-UCL.
DR GO; GO:0001714; P:endodermal cell fate specification; IDA:MGI.
DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:HGNC-UCL.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:MGI.
DR GO; GO:0045595; P:regulation of cell differentiation; IMP:HGNC-UCL.
DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC-UCL.
DR GO; GO:0035019; P:somatic stem cell population maintenance; IMP:UniProtKB.
DR GO; GO:0019827; P:stem cell population maintenance; IEP:BHF-UCL.
DR CDD; cd00086; homeodomain; 1.
DR InterPro; IPR009057; Homeobox-like_sf.
DR InterPro; IPR017970; Homeobox_CS.
DR InterPro; IPR001356; Homeobox_dom.
DR Pfam; PF00046; Homeodomain; 1.
DR SMART; SM00389; HOX; 1.
DR SUPFAM; SSF46689; SSF46689; 1.
DR PROSITE; PS00027; HOMEOBOX_1; 1.
DR PROSITE; PS50071; HOMEOBOX_2; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Activator; Alternative splicing; Developmental protein;
KW DNA-binding; Homeobox; Nucleus; Reference proteome; Repeat; Repressor;
KW Transcription; Transcription regulation.
FT CHAIN 1..305
FT /note="Homeobox protein NANOG"
FT /id="PRO_0000261418"
FT REPEAT 196..200
FT /note="1"
FT REPEAT 201..205
FT /note="2"
FT REPEAT 206..210
FT /note="3"
FT REPEAT 216..220
FT /note="4"
FT REPEAT 221..225
FT /note="5"
FT REPEAT 226..230
FT /note="6"
FT REPEAT 231..235
FT /note="7"
FT REPEAT 236..240
FT /note="8"
FT DNA_BIND 95..154
FT /note="Homeobox"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT REGION 1..96
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 122..151
FT /note="Required for DNA-binding"
FT /evidence="ECO:0000269|PubMed:25825768"
FT REGION 196..240
FT /note="8 X repeats starting with a Trp in each unit"
FT REGION 196..240
FT /note="Sufficient for transactivation activity"
FT /evidence="ECO:0000250"
FT REGION 241..305
FT /note="Sufficient for strong transactivation activity"
FT /evidence="ECO:0000250"
FT COMPBIAS 35..78
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 80..96
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT VAR_SEQ 168..183
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:16391521"
FT /id="VSP_021688"
FT VARIANT 82
FT /note="K -> N (in dbSNP:rs2889551)"
FT /evidence="ECO:0000269|PubMed:12787504,
FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15233988,
FT ECO:0000269|Ref.5"
FT /id="VAR_029384"
FT MUTAGEN 102
FT /note="F->A: No effect on POU5F1 promoter DNA-binding."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 122
FT /note="L->A: Increased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 124
FT /note="Q->A: Decreased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 125
FT /note="M->A: Decreased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 136
FT /note="Y->A: Decreased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 137
FT /note="K->A: Inhibits POU5F1 promoter DNA-binding."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 140
FT /note="K->A: Decreased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 141
FT /note="T->A: Inhibits POU5F1 promoter DNA-binding."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 144
FT /note="Q->A: No effect on POU5F1 promoter DNA-binding.
FT Decreased protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 145
FT /note="N->A: Inhibits POU5F1 promoter DNA-binding."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 147
FT /note="R->A: Inhibits POU5F1 promoter DNA-binding."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 148
FT /note="M->A: No effect on POU5F1 promoter DNA-binding.
FT Increased protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT MUTAGEN 151
FT /note="K->A: Decreased POU5F1 promoter DNA-binding and
FT protein stability."
FT /evidence="ECO:0000269|PubMed:25825768"
FT HELIX 104..116
FT /evidence="ECO:0007829|PDB:4RBO"
FT STRAND 117..119
FT /evidence="ECO:0007829|PDB:2KT0"
FT HELIX 122..131
FT /evidence="ECO:0007829|PDB:4RBO"
FT HELIX 136..152
FT /evidence="ECO:0007829|PDB:4RBO"
SQ SEQUENCE 305 AA; 34620 MW; AC3B2E067C591773 CRC64;
MSVDPACPQS LPCFEASDCK ESSPMPVICG PEENYPSLQM SSAEMPHTET VSPLPSSMDL
LIQDSPDSST SPKGKQPTSA EKSVAKKEDK VPVKKQKTRT VFSSTQLCVL NDRFQRQKYL
SLQQMQELSN ILNLSYKQVK TWFQNQRMKS KRWQKNNWPK NSNGVTQKAS APTYPSLYSS
YHQGCLVNPT GNLPMWSNQT WNNSTWSNQT QNIQSWSNHS WNTQTWCTQS WNNQAWNSPF
YNCGEESLQS CMQFQPNSPA SDLEAALEAA GEGLNVIQQT TRYFSTPQTM DLFLNYSMNM
QPEDV
